| |
| |
| Exchange: |
Nasdaq National Market |
| Security
Type: |
Common |
| Shares
Out: |
84,190,000 |
| Market
Cap: |
11.09(B) |
| Last
Volume: |
427,350 |
Avg
Vol: |
426,168 |
| 52
Week Range: |
$67.31 - $157.19 |
|
| Level
I Sector: |
Health Care |
| Level
II Sector: |
Drugs |
| Level
III Sector: |
Drug Manufacturers - Other |
|
Member Indexes:
|
| |
NASDAQ BIOTECHNOLOGY |
|
NASDAQ COMPOSITE |
| |
NASDAQ NNM COMPOSITE |
|
Rankings:
|
|
| Insider 3 Months : - |
| Insider 6 Months : - |
| Insider 3/6 Months : - |
|
| Guru Rank Number : 983 |
| Guru Rank Value : 0 |
| Guru Occurances : 1 |
|
|
|
|
|
| |
|
Company Profile Sarepta Therapeutics is a commercial-stage biopharmaceutical company focused on helping patients through the discovery and development of RNA-targeted therapeutics, gene therapy and other genetic therapeutic modalities for the treatment of rare diseases. Co. is developing therapeutic candidates for a range of diseases and disorders, including Duchenne muscular dystrophy, Limb-girdle muscular dystrophies and other neuromuscular and central nervous system related disorders. Co.'s commercial product, EXONDYS 51® (eteplirsen) Injection is indicated for the treatment of Duchenne in patients who have a confirmed mutation of the dystrophin gene that is amenable to exon 51 skipping.
|
|
|
D/I:
|
|
|
D
is for direct shares.
I is
for indirect shares.
D/I
refers to the Direct or Indirect
shares traded vs. held. |
|
|
|
Forms:
|
|
|
A
Form 4 is a form filed
by an insider to indicate a change
in ownership.
A Form
3 is a form filed by
an insider to indicate an
initial ownership of a security. |
|
|
|
3m +/-:
|
|
|
|
This
represents the company's 3 month
price change. The initial price
is based on the closing price
of the stock on the day the transaction
took place. Purchases & sales
are viewed as long & short
positions respectively.
|
|
|
|
Actions:
|
|
|
| B |
Buy |
| S |
Sell |
| OE |
Option
Exercised |
| A |
Acquired |
| D |
Disposed |
| AB |
Automatic
Buy |
| AS |
Automatic
Sell |
| IO |
Initial
Ownership |
|
|
|
|
Download:
|
|
|
Download only Transactions
Forms. (Default)
Download
only Summary Infomation.
Download
both Transactions and Summary Data
|
|
|
|
|
| |
| |
Summary (Direct Transactions Only)  |
3 Months |
6 Months |
12 Months |
24 Months |
| Total Shares Bought |
0 |
0 |
143,757 |
247,027 |
| Total Buy Value |
$0 |
$0 |
$13,295,068 |
$24,257,422 |
| Total People Bought |
0 |
0 |
3 |
3 |
| Total Buy Transactions |
0 |
0 |
5 |
7 |
| Total Shares Sold |
27,731 |
27,731 |
42,731 |
43,589 |
| Total Sell Value |
$3,499,041 |
$3,499,041 |
$5,099,841 |
$5,194,152 |
| Total People Sold |
7 |
7 |
7 |
7 |
| Total Sell Transactions |
7 |
7 |
8 |
9 |
| End Date |
2024-02-11 |
2023-11-10 |
2023-05-12 |
2022-05-12 |
|
| Filer's Name |
Relation Title |
Off-Dir-10% |
Tran. Date |
Form |
Action |
Price |
Mkt Value |
D/I |
Shares |
Holdings |
Rank
|
|
|
| 3m +/- |
|
|
Form |
  Mahatme Sandesh |
EVP, CFO & CBO |
• – – |
2018-03-15 |
4 |
OE |
$23.85 |
$59,625 |
D/D |
2,500 |
43,395 |
|
- |
|
| Ruff Shamim |
SVP, Chief Regulatory Affairs |
• – – |
2018-03-15 |
4 |
D |
$81.22 |
$59,778 |
D/D |
(736) |
28,809 |
|
- |
|
| Ruff Shamim |
SVP, Chief Regulatory Affairs |
• – – |
2018-03-15 |
4 |
OE |
$13.90 |
$59,813 |
D/D |
2,500 |
29,465 |
|
- |
|
| Wigzell Hans Lennart Rudolf |
Director |
– • – |
2018-03-05 |
4 |
A |
$0.00 |
$0 |
D/D |
3,418 |
10,084 |
|
- |
|
| Behrens M Kathleen |
Director |
– • – |
2018-03-05 |
4 |
A |
$0.00 |
$0 |
D/D |
3,418 |
116,534 |
|
- |
|
| Barry Richard |
Director |
– • – |
2018-03-05 |
4 |
A |
$0.00 |
$0 |
D/D |
3,418 |
3,245,432 |
|
- |
|
| Bonney Michael W |
Director |
– • – |
2018-03-05 |
4 |
A |
$0.00 |
$0 |
D/D |
3,418 |
3,418 |
|
- |
|
| Nicaise Claude |
Director |
– • – |
2018-03-05 |
4 |
A |
$0.00 |
$0 |
D/D |
3,418 |
5,418 |
|
- |
|
| Wigzell Hans Lennart Rudolf |
Director |
– • – |
2017-11-30 |
4 |
S |
$55.89 |
$372,619 |
D/D |
(6,667) |
6,666 |
|
- |
|
| Wigzell Hans Lennart Rudolf |
Director |
– • – |
2017-11-30 |
4 |
OE |
$7.38 |
$49,202 |
D/D |
6,667 |
13,333 |
|
- |
|
| Ingram Douglas S |
President & CEO |
• • – |
2017-11-08 |
4 |
B |
$52.44 |
$1,999,957 |
D/D |
38,138 |
420,196 |
2.81 |
- |
|
| Ruff Shamim |
SVP, Regulatory Affairs & Qual |
• – – |
2017-11-06 |
4 |
AS |
$55.00 |
$550,000 |
D/D |
(10,000) |
27,045 |
|
- |
|
| Ruff Shamim |
SVP, Regulatory Affairs & Qual |
• – – |
2017-11-06 |
4 |
OE |
$14.76 |
$147,600 |
D/D |
10,000 |
37,045 |
|
- |
|
| Ruff Shamim |
SVP, Regulatory Affairs & Qual |
• – – |
2017-10-03 |
4 |
AS |
$50.00 |
$575,000 |
D/D |
(11,500) |
27,045 |
|
- |
|
| Ruff Shamim |
SVP, Regulatory Affairs & Qual |
• – – |
2017-10-03 |
4 |
OE |
$14.76 |
$169,740 |
D/D |
11,500 |
38,545 |
|
- |
|
| Howton David T |
SVP, General Counsel |
• – – |
2017-08-03 |
4 |
D |
$37.88 |
$175,839 |
D/D |
(4,642) |
29,298 |
|
- |
|
| Howton David T |
SVP, General Counsel |
• – – |
2017-08-03 |
4 |
OE |
$0.00 |
$0 |
D/D |
10,639 |
33,940 |
|
- |
|
| Kaye Edward M. Md |
Director |
– • – |
2017-08-03 |
4 |
D |
$37.88 |
$632,710 |
D/D |
(16,703) |
71,229 |
|
- |
|
| Kaye Edward M. Md |
Director |
– • – |
2017-08-03 |
4 |
OE |
$0.00 |
$0 |
D/D |
35,461 |
87,932 |
|
- |
|
| Mahatme Sandesh |
EVP, CFO & CBO |
• – – |
2017-08-03 |
4 |
D |
$37.88 |
$237,280 |
D/D |
(6,264) |
40,895 |
|
- |
|
| Mahatme Sandesh |
EVP, CFO & CBO |
• – – |
2017-08-03 |
4 |
OE |
$0.00 |
$0 |
D/D |
13,298 |
47,159 |
|
- |
|
| Ruff Shamim |
SVP, Regulatory Affairs & Qual |
• – – |
2017-08-03 |
4 |
D |
$37.88 |
$109,170 |
D/D |
(2,882) |
27,045 |
|
- |
|
| Ruff Shamim |
SVP, Regulatory Affairs & Qual |
• – – |
2017-08-03 |
4 |
OE |
$0.00 |
$0 |
D/D |
8,865 |
29,927 |
|
- |
|
| Cumbo Alexander |
SVP, Chief Commercial Officer |
• – – |
2017-08-03 |
4 |
D |
$37.88 |
$120,042 |
D/D |
(3,169) |
23,458 |
|
- |
|
| Cumbo Alexander |
SVP, Chief Commercial Officer |
• – – |
2017-08-03 |
4 |
OE |
$0.00 |
$0 |
D/D |
9,752 |
26,627 |
|
- |
|
360 Records found
|
|
Page 11 of 15 |
|
|
0.12 (0.09%) 
